FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Teru Hideshima

Research Profile

Disorders

Multiple Myeloma

Chemicals & Drugs

Anatomy

Living Beings

Physiology

Phenomena

Phosphorylation

Co-author Network

Publications

TOP 3
Güllü Topal Görgün; Teru Hideshima; Jacob Laubach; Craig Maguire; Nikhil C Munshi; Noopur Raje; Paul G Richardson; Gregory Whitehill; Jennifer L Anderson; Kenneth C Anderson
Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans.
Samantha Pozzi; Loredana Santo; David Scadden; Linda Schirtzinge; Sonia Vallet; Hua Yan; Kenneth C Anderson; Diana Cirstea; Homare Eda; Mariateresa Fulciniti; Teru Hideshima; Henry M Kronenberg; Stuart Kuhstoss; Nikhil Munshi; Kishan Patel; Noopur Raje
In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma.
Teru Hideshima; Kenneth C Anderson
Histone deacetylase inhibitors in the treatment for multiple myeloma.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Teru Hideshima (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Güllü Topal Görgün; Teru Hideshima; Jacob Laubach; Craig Maguire; Nikhil C Munshi; Noopur Raje; Paul G Richardson; Gregory Whitehill; Jennifer L Anderson; Kenneth C Anderson
Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans.
Blood 2013;121(15):2975-87.
2013: Samantha Pozzi; Loredana Santo; David Scadden; Linda Schirtzinge; Sonia Vallet; Hua Yan; Kenneth C Anderson; Diana Cirstea; Homare Eda; Mariateresa Fulciniti; Teru Hideshima; Henry M Kronenberg; Stuart Kuhstoss; Nikhil Munshi; Kishan Patel; Noopur Raje
In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma.
Bone 2013;53(2):487-96.
2013: Teru Hideshima; Kenneth C Anderson
Histone deacetylase inhibitors in the treatment for multiple myeloma.
International journal of hematology 2013;97(3):324-32.
2013: Michele Cea; Marco Gobbi; Teru Hideshima; Franco Patrone; Paul G Richardson; Antonia Cagnetta; Kenneth C Anderson
New insights into the treatment of multiple myeloma with histone deacetylase inhibitors.
Current pharmaceutical design 2013;19(4):734-44.
2012: Panisinee Lawasut; Michelle Maglio; Constantine Mitsiades; Kenneth C Anderson; Dharminder Chauhan; Claire Fabre; Catriona Hayes; Teru Hideshima; Jacob Laubach; Paul G Richardson
New proteasome inhibitors in myeloma.
Current hematologic malignancy reports 2012;7(4):258-66.
2012: Michele Cea; Dharminder Chauhan; Francesca Cottini; Mariateresa Fulciniti; Marco Gobbi; Teru Hideshima; Jana Jakubikova; Sun-Young Kong; Nikhil Munshi; Alessio Nencioni; Franco Patrone; Paul Richardson; Aldo Roccaro; Antonio Sacco; Yu-Tzu Tai; Antonia Cagnetta; Teresa Calimeri; Kenneth C Anderson
Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition.
Blood 2012;120(17):3519-29.
2012: Dharminder Chauhan; Mariaterresa Fulcinniti; Teru Hideshima; Benedikt M Kessler; William D Kingsbury; Matthew P Kodrasov; K G Suresh Kumar; Craig A Leach; Jeffrey L McDermott; Stephane Minvielle; Nikhil Munshi; Benjamin Nicholson; Robert Orlowski; Paul Richardson; Parantu K Shah; Ze Tian; Joseph Weinstock; Bin Zhou; Mikael Altun; Ruben Carrasco; Kenneth C Anderson
A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance.
Cancer cell 2012;22(3):345-58.
2012: Claire Fabre; Güllü Gorgun; Teru Hideshima; Yiguo Hu; Sun-Young Kong; Jeffrey Meshulam; Naoya Mimura; Jiro Minami; Hiroto Ohguchi; Paul G Richardson; Yu-Tzu Tai; Jie Zhang; Kathryn Bobb; Ruben D Carrasco; Diana Cirstea; Kenneth C Anderson
Dual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myeloma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(17):4669-81.
2012: Ying Wang; Kenneth C Anderson; Teru Hideshima; Jacob P Laubach; Aleksey Lomakin; Nikhil C Munshi; Olutayo Ogun; Paul G Richardson; George B. Benedek
Pathological crystallization of human immunoglobulins.
Proceedings of the National Academy of Sciences of the United States of America 2012;109(33):13359-61.
2012: Andrzej J Jakubowiak; Malathi Kandarpa; Jonathan L Kaufman; Stephanie Kraftson; Enrique Poradosu; Paul G Richardson; Charles W Ross; Peter Sportelli; Todd Zimmerman; Lesa Gardner; Kathy Giusti; Colleen Harvey; Teru Hideshima; Melissa Alsina; Kenneth C Anderson
Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study.
British journal of haematology 2012;158(4):472-80.
2012: Teru Hideshima; Kenneth C Anderson
Biologic impact of proteasome inhibition in multiple myeloma cells--from the aspects of preclinical studies.
Seminars in hematology 2012;49(3):223-7.
2012: Merav Leiba; Constantine S Mitsiades; Arnon Nagler; Mark Pines; Paul G Richardson; Yu-Tzu Tai; Teru Hideshima; Jana Jakubikova; Steffen Klippel; Adi Leiba; Kenneth C Anderson
Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents.
British journal of haematology 2012;157(6):718-31.
2012: Paul G Richardson; Cathy Eng; Teru Hideshima; Jill Kolesar; Kenneth C Anderson
Perifosine , an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity.
Expert opinion on drug metabolism & toxicology 2012;8(5):623-33.
2012: Paul G Richardson; Robert L Schlossman; Diane Warren; Kathleen Colson; Deborah Doss; Irene M Ghobrial; Teru Hideshima; Jacob P Laubach; Laura Lunde; Mary McKenney; Constantine S Mitsiades; Nikhil C Munshi; Kimberly Noonan; Katherine C Redman; Kenneth C Anderson
The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib.
European journal of haematology 2012;88(5):446-9.
2012: Kumar Sukhdeo; K Takada; Kenneth C Anderson; Teru Hideshima; S Ito; M Mani; G Mendez; V Pena-Cruz; D R Carrasco
β-catenin is dynamically stored and cleared in multiple myeloma by the proteasome-aggresome-autophagosome-lysosome pathway.
Leukemia 2012;26(5):1116-9.
2012: Loredana Santo; Tyler Scullen; David Tamang; Jen-Chieh Tseng; John H van Duzer; Min Yang; Scott Rodig; Kenneth C Anderson; James E Bradner; Miriam Canavese; Diana Cirstea; Homare Eda; Teru Hideshima; Matthew Jarpe; Simon S Jones; Andrew L Kung; Ralph Mazitschek; Walter C Ogier; Noopur Raje
Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.
Blood 2012;119(11):2579-89.
2012: Niels Wcj van de Donk; Güllü Görgün; Richard Wj Groen; Teru Hideshima; Jana Jakubikova; Jacob Laubach; Henk M Lokhorst; Constantine S Mitsiades; Inger S Nijhof; Reinier A Raymakers; Paul G Richardson; Kenneth C Anderson
Lenalidomide for the treatment of relapsed and refractory multiple myeloma.
Cancer management and research 2012;4():253-68.
2011: Paul G Richardson; Robert Schlossman; Peter Sportelli; Jeff Wolf; Jeffrey A Zonder; Jeff Allerton; Michael Bar; Kathleen Colson; John Densmore; Lesa Gardner; Irene M Ghobrial; Teru Hideshima; David Irwin; Andrzej J Jakubowiak; Amrita Krishnan; Jacob Laubach; Sagar Lonial; Tom Martin; Nikhil Munshi; Enrique Poradosu; Noopur Raje; Kenneth C Anderson
Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(32):4243-9.
2011: Teru Hideshima; Paul G Richardson; Kenneth C Anderson
Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma.
Molecular cancer therapeutics 2011;10(11):2034-42.
2011: Mariateresa Fulciniti; Teru Hideshima; Cheng Li; Stephane Minvielle; Puru Nanjappa; Rao Prabhala; Scott Rodig; Yu-Tzu Tai; Pierfrancesco Tassone; Samir Amin; Kenneth C Anderson; Herve Avet-Loiseau; Nikhil C Munshi
Significant biological role of sp1 transactivation in multiple myeloma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(20):6500-9.
2011: Teru Hideshima; Kenneth C Anderson
Novel therapies in MM: from the aspect of preclinical studies.
International journal of hematology 2011;94(4):344-54.
2011: Jana Jakubikova; Kihyun Kim; Steffen Klippel; Merav Leiba; Douglas W McMillin; Kenneth C Anderson; Simona Blotta; David Cervi; Dana Cholujova; John F Daley; Jake Delmore; Teru Hideshima; Sabikun Nahar; Joseph Negri; Melissa Ooi; Paul G Richardson; Jan Sedlak; Constantine S Mitsiades
Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myeloma.
Haematologica 2011;96(8):1170-9.
2011: Sonia Vallet; P Veiby; Loredana Santo; D T Scadden; N Vaghela; Kenneth C Anderson; D Cirstea; Mariateresa Fulciniti; Teru Hideshima; K Patel; S Pozzi; Noopur Raje
A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function.
Leukemia 2011;25(7):1174-81.
2011: Loredana Santo; Teru Hideshima; Diana Cirstea; Madhavi Bandi; Erik A Nelson; Gullu Gorgun; Scott Rodig; Sonia Vallet; Samantha Pozzi; Kishan Patel; Christine Unitt; Matt Squires; Yiguo Hu; Dharminder Chauhan; Anuj Mahindra; Nikhil C Munshi; Kenneth C Anderson; Noopur Raje
Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(10):3259-71.
2011: W Song; Yu-Tzu Tai; Z Tian; Teru Hideshima; Dharminder Chauhan; P Nanjappa; Mark A Exley; Kenneth C Anderson; Nikhil C Munshi
HDAC inhibition by LBH589 affects the phenotype and function of human myeloid dendritic cells.
Leukemia 2011;25(1):161-8.
2010: Anuj Mahindra; Teru Hideshima; Kenneth C Anderson
Multiple myeloma: biology of the disease.
Blood reviews 2010;24 Suppl 1():S5-11.
2010: Güllü Görgün; Elisabetta Calabrese; Ender Soydan; Teru Hideshima; Giulia Perrone; Madhavi Bandi; Diana Cirstea; Loredana Santo; Yiguo Hu; Yu-Tzu Tai; Sabikun Nahar; Naoya Mimura; Claire Fabre; Noopur Raje; Nikhil Munshi; Paul Richardson; Kenneth C Anderson
Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma.
Blood 2010;116(17):3227-37.
2010: Hiroshi Ikeda; Teru Hideshima; Mariateresa Fulciniti; Giulia Perrone; Naoya Miura; Hiroshi Yasui; Yutaka Okawa; Tanyel Kiziltepe; Loredana Santo; Sonia Vallet; Diana Cristea; Elisabetta Calabrese; Gullu Gorgun; Noopur S Raje; Paul G Richardson; Nikhil C Munshi; Brian J Lannutti; Kamal D Puri; Neill A Giese; Kenneth C Anderson
PI3K/p110{delta} is a novel therapeutic target in multiple myeloma.
Blood 2010;116(9):1460-8.
2010: Paul G Richardson; Edie Weller; Sagar Lonial; Andrzej J Jakubowiak; Sundar Jagannath; Noopur S Raje; David Avigan; Wanling Xie; Irene M Ghobrial; Robert Schlossman; Amitabha Mazumder; Nikhil C Munshi; David H Vesole; Robin Joyce; Jonathan L Kaufman; Deborah Doss; Diane L Warren; Laura E Lunde; Sarah Kaster; Carol Delaney; Teru Hideshima; Constantine S Mitsiades; Robert Knight; Dixie Esseltine; Kenneth C Anderson
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Blood 2010;116(5):679-86.
2010: Güllü Görgün; Elisabetta Calabrese; Teru Hideshima; Jeffrey Ecsedy; Giulia Perrone; Mala Mani; Hiroshi Ikeda; Giada Bianchi; Yiguo Hu; Diana Cirstea; Loredana Santo; Yu-Tzu Tai; Sabikun Nahar; Mei Zheng; Madhavi Bandi; Ruben D Carrasco; Noopur Raje; Nikhil Munshi; Paul Richardson; Kenneth C Anderson
A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma.
Blood 2010;115(25):5202-13.
2010: Teru Hideshima; Constantine S Mitsiades; Hiroshi Ikeda; Dharminder Chauhan; Noopur Raje; Gullu Gorgun; Hiromasa Hideshima; Nikhil C Munshi; Paul G Richardson; Daniel R Carrasco; Kenneth C Anderson
A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells.
Blood 2010;115(18):3772-5.
2010: Kihyun Kim; Sun-Young Kong; Mariateresa Fulciniti; Xianfeng Li; Weihua Song; Sabikun Nahar; Peter C Burger; Mathew J Rumizen; klaus podar; Dharminder Chauhan; Teru Hideshima; Nikhil C Munshi; Paul Richardson; Ann Clark; Janet Ogden; Andreas Goutopoulos; Luca Rastelli; Kenneth C Anderson; Yu-Tzu Tai
Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo.
British journal of haematology 2010;149(4):537-49.
2010: Diana Cirstea; Teru Hideshima; Scott Rodig; Loredana Santo; Samantha Pozzi; Sonia Vallet; Hiroshi Ikeda; Giulia Perrone; Gullu Gorgun; Kishan Patel; Neil Desai; Peter Sportelli; Shweta Kapoor; Shireen Vali; Siddhartha Mukherjee; Nikhil C Munshi; Kenneth C Anderson; Noopur Raje
Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma.
Molecular cancer therapeutics 2010;9(4):963-75.
2010: Sonia Vallet; Siddhartha Mukherjee; Nileshwari Vaghela; Teru Hideshima; Mariateresa Fulciniti; Samantha Pozzi; Loredana Santo; Diana Cirstea; Kishan Patel; Aliyah R Sohani; Alex Guimaraes; Wanling Xie; Dharminder Chauhan; Jesse A Schoonmaker; Eyal Attar; Michael Churchill; Edie Weller; Nikhil Munshi; Jasbir S Seehra; Ralph Weissleder; Kenneth C Anderson; David T Scadden; Noopur Raje
Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease.
Proceedings of the National Academy of Sciences of the United States of America 2010;107(11):5124-9.
2010: Paul G Richardson; Jacob Laubach; Anuj Mahindra; Constantine Mitsiades; Robert Schlossman; Irene Ghobrial; Teru Hideshima; Noopur Raje; Nikhil Munshi; Kenneth C Anderson
The treatment of multiple myeloma patients not eligible for asct.
Mediterranean journal of hematology and infectious diseases 2010;2(2):e2010009.
2010: Paul Richardson; Constantine Mitsiades; Jacob Laubach; Robert Schlossman; Irene Ghobrial; Teru Hideshima; Nikhil Munshi; Kenneth C Anderson
Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy.
Core evidence 2010;4():215-45.
2009: Mariateresa Fulciniti; Teru Hideshima; Claudine Vermot-Desroches; Samantha Pozzi; Puru Nanjappa; Zhenxin Shen; Nipun Patel; Ernest S Smith; Wei Wang; Rao Prabhala; Yu-Tzu Tai; Pierfrancesco Tassone; Kenneth C Anderson; Nikhil C Munshi
A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(23):7144-52.
2009: Melissa G Ooi; Patrick J Hayden; Vassiliki Kotoula; Douglas W McMillin; Elpida Charalambous; Emily Daskalaki; Noopur S Raje; Nikhil C Munshi; Dharminder Chauhan; Teru Hideshima; Leutz Buon; Martin Clynes; Peter O'Gorman; Paul G Richardson; Constantine S Mitsiades; Kenneth C Anderson; Nicholas Mitsiades
Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(23):7153-60.
2009: Paul G Richardson; Edie Weller; Sundar Jagannath; David Avigan; Melissa Alsina; Robert Schlossman; Amitabha Mazumder; Nikhil C Munshi; Irene M Ghobrial; Deborah Doss; Diane L Warren; Laura E Lunde; Mary McKenney; Carol Delaney; Constantine S Mitsiades; Teru Hideshima; William Dalton; Robert Knight; Dixie Esseltine; Kenneth C Anderson
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(34):5713-9.
2009: Joseph M Negri; Douglas W McMillin; Jake Delmore; Nicholas Mitsiades; Patrick Hayden; Steffen Klippel; Teru Hideshima; Dharminder Chauhan; Nikhil C Munshi; Carolyn A Buser; John Pollard; Paul G Richardson; Kenneth C Anderson; Constantine S Mitsiades
In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465.
British journal of haematology 2009;147(5):672-6.
2009: J P Laubach; A Mahindra; Constantine S Mitsiades; R L Schlossman; Nikhil C Munshi; I M Ghobrial; N Carreau; Teru Hideshima; Kenneth C Anderson; Paul G Richardson
The use of novel agents in the treatment of relapsed and refractory multiple myeloma.
Leukemia 2009;23(12):2222-32.
2009: Dharminder Chauhan; Ajita V Singh; Mohan Brahmandam; Ruben Carrasco; Madhavi Bandi; Teru Hideshima; Giada Bianchi; klaus podar; Yu-Tzu Tai; Constantine Mitsiades; Noopur Raje; David L Jaye; Shaji K Kumar; Paul Richardson; Nikhil C Munshi; Kenneth C Anderson
Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target.
Cancer cell 2009;16(4):309-23.
2009: Jacob P Laubach; Constantine S Mitsiades; Anuj Mahindra; Robert L Schlossman; Teru Hideshima; Dharminder Chauhan; Nicole A Carreau; Irene M Ghobrial; Noopur Raje; Nikhil C Munshi; Kenneth C Anderson; Paul G Richardson
Novel therapies in the treatment of multiple myeloma.
Journal of the National Comprehensive Cancer Network : JNCCN 2009;7(9):947-60.
2009: Jui Dutta-Simmons; Yunyu Zhang; Gullu T Gorgun; Moshe Gatt; Mala Mani; Teru Hideshima; Kohichi Takada; Nicole E Carlson; Daniel E Carrasco; Yu-Tzu Tai; Noopur Raje; Anthony Letai; Kenneth C Anderson; Daniel R Carrasco
Aurora kinase A is a target of Wnt/beta-catenin involved in multiple myeloma disease progression.
Blood 2009;114(13):2699-708.
2009: Samantha Pozzi; Sonia Vallet; Siddhartha Mukherjee; Diana Cirstea; Nileshwari Vaghela; Loredana Santo; Eyal Rosen; Hiroshi Ikeda; Yutaka Okawa; Tanyel Kiziltepe; Jesse Schoonmaker; Wanling Xie; Teru Hideshima; Edie Weller; Mary L Bouxsein; Nikhil C Munshi; Kenneth C Anderson; Noopur Raje
High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(18):5829-39.
2009: Teru Hideshima; Hiroshi Ikeda; Dharminder Chauhan; Yutaka Okawa; Noopur Raje; klaus podar; Constantine S Mitsiades; Nikhil C Munshi; Paul G Richardson; Ruben D Carrasco; Kenneth C Anderson
Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.
Blood 2009;114(5):1046-52.
2009: Mariateresa Fulciniti; Pierfrancesco Tassone; Teru Hideshima; Sonia Vallet; Puru Nanjappa; Seth A Ettenberg; Zhenxin Shen; Nipun Patel; Yu-Tzu Tai; Dharminder Chauhan; Constantine S Mitsiades; Rao H Prabhala; Noopur Raje; Kenneth C Anderson; David R Stover; Nikhil C Munshi
Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma.
Blood 2009;114(2):371-9.
2009: Jing Zhang; Martin Sattler; Giovanni Tonon; Clemens Grabher; Samir Lababidi; Alexander Zimmerhackl; Marc S Raab; Sonia Vallet; Yiming Zhou; Marie-Astrid Cartron; Teru Hideshima; Yu-Tzu Tai; Dharminder Chauhan; Kenneth C Anderson; Klaus Podar
Targeting angiogenesis via a c-Myc/hypoxia-inducible factor-1alpha-dependent pathway in multiple myeloma.
Cancer research 2009;69(12):5082-90.
2009: Hiroshi Ikeda; Teru Hideshima; Mariateresa Fulciniti; Robert J Lutz; Hiroshi Yasui; Yutaka Okawa; Tanyel Kiziltepe; Sonia Vallet; Samantha Pozzi; Loredana Santo; Giulia Perrone; Yu-Tzu Tai; Diana Cirstea; Noopur S Raje; Christoph Uherek; Benjamin Dälken; Silke Aigner; Frank Osterroth; Nikhil Munshi; Paul G Richardson; Kenneth C Anderson
The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(12):4028-37.
2009: Teru Hideshima; Dharminder Chauhan; Tanyel Kiziltepe; Hiroshi Ikeda; Yutaka Okawa; klaus podar; Noopur Raje; Alexei Protopopov; Nikhil C Munshi; Paul G Richardson; Ruben D Carrasco; Kenneth C Anderson
Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications.
Blood 2009;113(21):5228-36.
2009: Yu-Tzu Tai; Ender Soydan; Weihua Song; Mariateresa Fulciniti; Kihyun Kim; Fangxin Hong; Xian-Feng Li; Peter C Burger; Matthew J Rumizen; Sabikun Nahar; klaus podar; Teru Hideshima; Nikhil C Munshi; Giovanni Tonon; Ruben D Carrasco; Daniel E H Afar; Kenneth C Anderson
CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells.
Blood 2009;113(18):4309-18.
2009: Abdel Kareem Azab; Judith M Runnels; Costas Pitsillides; Anne-Sophie Moreau; Feda Azab; Xavier Leleu; Xiaoying Jia; Renee Wright; Beatriz Ospina; Alicia L Carlson; Clemens Alt; Nicholas Burwick; Aldo Roccaro; Hai T Ngo; Mena Farag; Molly R Melhem; Antonio Sacco; Nikhil C Munshi; Teru Hideshima; Barrett J Rollins; Kenneth C Anderson; Andrew L Kung; Charles P Lin; Irene M Ghobrial
CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.
Blood 2009;113(18):4341-51.
2009: Constantine S Mitsiades; Teru Hideshima; Dharminder Chauhan; Douglas W McMillin; Steffen Klippel; Jacob P Laubach; Nikhil C Munshi; Kenneth C Anderson; Paul G Richardson
Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib.
Seminars in hematology 2009;46(2):166-75.
2009: klaus podar; Yu-Tzu Tai; Teru Hideshima; Sonia Vallet; Paul G Richardson; Kenneth C Anderson
Emerging therapies for multiple myeloma.
Expert opinion on emerging drugs 2009;14(1):99-127.
2009: Marc S Raab; Iris Breitkreutz; Giovanni Tonon; Jing Zhang; Patrick J Hayden; Thu Nguyen; Johannes H Fruehauf; Boris K Lin; Dharminder Chauhan; Teru Hideshima; Nikhil C Munshi; Kenneth C Anderson; Klaus Podar
Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling.
Blood 2009;113(7):1513-21.
2009: Yutaka Okawa; Teru Hideshima; Paul Steed; Sonia Vallet; Steven Hall; Ken Huang; John Rice; Amy Barabasz; Brianna Foley; Hiroshi Ikeda; Noopur Raje; Tanyel Kiziltepe; Hiroshi Yasui; Sotaro Enatsu; Kenneth C Anderson
SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK.
Blood 2009;113(4):846-55.
2009: Jacob P Laubach; Constantine S Mitsiades; Teru Hideshima; Robert Schlossman; Dharminder Chauhan; Nikhil Munshi; Irene Ghobrial; Nicole Carreau; Kenneth C Anderson; Paul G Richardson
Bortezomib in the management of multiple myeloma.
Cancer management and research 2009;1():107-17.
2009: Renate Burger; Steven Le Gouill; Yu-Tzu Tai; Reshma Shringarpure; Pierfrancesco Tassone; Paola Neri; klaus podar; Laurence Catley; Teru Hideshima; Dharminder Chauhan; Eian Caulder; Claire L Neilan; Kris Vaddi; Jun Li; Martin Gramatzki; Jordan S Fridman; Kenneth C Anderson
Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo.
Molecular cancer therapeutics 2009;8(1):26-35.
2008: Erik A Nelson; Sarah R Walker; Alicia Kepich; Laurie B Gashin; Teru Hideshima; Hiroshi Ikeda; Dharminder Chauhan; Kenneth C Anderson; David A Frank
Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3.
Blood 2008;112(13):5095-102.
2008: Yu-Tzu Tai; Myles Dillon; Weihua Song; Merav Leiba; Xian-Feng Li; Peter C Burger; Alfred I Lee; klaus podar; Teru Hideshima; Audie G Rice; A van Abbema; Lynne Jesaitis; Ingrid Caras; Debbie Law; Edie Weller; Wanling Xie; Paul G Richardson; Nikhil C Munshi; Claire Mathiot; Hervé Avet-Loiseau; Daniel E H Afar; Kenneth C Anderson
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu.
Blood 2008;112(4):1329-37.
2008: Constantine S Mitsiades; Enrique M Ocio; Atanasio Pandiella; Patricia Maiso; Consuelo Gajate; Mercedes Garayoa; David Vilanova; Juan Carlos Montero; Nicholas Mitsiades; Ciaran J McMullan; Nikhil C Munshi; Teru Hideshima; Dharminder Chauhan; Pablo Aviles; Gabriel Otero; Glynn Faircloth; M Victoria Mateos; Paul G Richardson; Faustino Mollinedo; Jesus F San-Miguel; Kenneth C Anderson
Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo.
Cancer research 2008;68(13):5216-25.
2008: Paul G Richardson; Constantine S Mitsiades; Robert Schlossman; Irene M Ghobrial; Teru Hideshima; Nikhil C Munshi; Kenneth C Anderson
Bortezomib in the front-line treatment of multiple myeloma.
Expert review of anticancer therapy 2008;8(7):1053-72.
2008: Xavier Leleu; Jérôme Eeckhoute; Xiaoying Jia; Aldo Roccaro; Anne-Sophie Moreau; Mena Farag; Antonio Sacco; Hai T Ngo; Judith M Runnels; Molly R Melhem; Nicolas Burwick; Abdelkareem Azab; Feda Azab; Zachary Hunter; Evdoxia Hatjiharissi; Daniel R Carrasco; Steve P Treon; Thomas E Witzig; Teru Hideshima; Myles Brown; Kenneth C Anderson; Irene M Ghobrial
Targeting NF-kappaB in Waldenstrom macroglobulinemia.
Blood 2008;111(10):5068-77.
2008: Yutaka Okawa; Teru Hideshima; Hiroshi Ikeda; Noopur Raje; Sonia Vallet; Tanyel Kiziltepe; Hiroshi Yasui; Sotaro Enatsu; Samantha Pozzi; Iris Breitkreutz; Diana Cirstea; Loredana Santo; Paul G Richardson; Kenneth C Anderson
Fatty acid synthase is a novel therapeutic target in multiple myeloma.
British journal of haematology 2008;141(5):659-71.
2008: Kenji Ishitsuka; Teru Hideshima; Paola Neri; Sonia Vallet; Norihiko Shiraishi; Yutaka Okawa; Zhenxin Shen; Noopur Raje; Tanyel Kiziltepe; Enrique M Ocio; Dharminder Chauhan; Pierfrancesco Tassone; Nikhil C Munshi; Robert M Campbell; Alfonso De Dios; Chuan Shih; James J Starling; Kazuo Tamura; Kenneth C Anderson
p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications.
British journal of haematology 2008;141(5):598-606.
2008: Aldo Roccaro; Xavier Leleu; Antonio Sacco; Xiaoying Jia; Molly Melhem; Anne-Sophie Moreau; Hai T Ngo; Judith M Runnels; Abdelkareem Azab; Feda Azab; Nicholas Burwick; Mena Farag; Steve P Treon; Michael A Palladino; Teru Hideshima; Dharminder Chauhan; Kenneth C Anderson; Irene M Ghobrial
Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia.
Blood 2008;111(9):4752-63.
2008: Noopur Raje; Sook-Bin Woo; Karen Hande; Jeff T Yap; Paul G Richardson; Sonia Vallet; Nathaniel S Treister; Teru Hideshima; Niall Sheehy; Shweta Chhetri; Brendan Connell; Wanling Xie; Yu-Tzu Tai; Agnieszka Szot-Barnes; Mei Tian; Robert Schlossman; Edie Weller; Nikhil C Munshi; Annick D Van den Abbeele; Kenneth C Anderson
Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(8):2387-95.
2008: Teru Hideshima; Noopur Raje; Paul G Richardson; Kenneth C Anderson
A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma.
Therapeutics and clinical risk management 2008;4(1):129-36.
2008: Alissa Huston; Xavier Leleu; Xiaoying Jia; Anne-Sophie Moreau; Hai T Ngo; Judith Runnels; Judy Anderson; Yazan Alsayed; Aldo Roccaro; Sonia Vallet; Evdoxia Hatjiharissi; Yu-Tzu Tai; Peter Sportelli; Nikhil C Munshi; Paul G Richardson; Teru Hideshima; David G Roodman; Kenneth C Anderson; Irene M Ghobrial
Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(3):865-74.
2008: Siddhartha Mukherjee; Noopur Raje; Jesse A Schoonmaker; Julie C Liu; Teru Hideshima; Marc N Wein; Dallas C Jones; Sonia Vallet; Mary L Bouxsein; Samantha Pozzi; Shweta Chhetri; Y David Seo; Joshua P Aronson; Chirayu Patel; Mariateresa Fulciniti; Louise E Purton; Laurie H Glimcher; Jane B Lian; Gary Stein; Kenneth C Anderson; David T Scadden
Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice.
The Journal of clinical investigation 2008;118(2):491-504.
2008: Dharminder Chauhan; Ajita Singh; Mohan Brahmandam; klaus podar; Teru Hideshima; Paul Richardson; Nikhil C Munshi; Michael A Palladino; Kenneth C Anderson
Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma.
Blood 2008;111(3):1654-64.
2008: klaus podar; S L Gouill; J Zhang; J T Opferman; E Zorn; Yu-Tzu Tai; Teru Hideshima; M Amiot; Dharminder Chauhan; Jean-Luc Harousseau; Kenneth C Anderson
A pivotal role for Mcl-1 in Bortezomib-induced apoptosis.
Oncogene 2008;27(6):721-31.
2008: Dharminder Chauhan; Teru Hideshima; Kenneth C Anderson
Targeting proteasomes as therapy in multiple myeloma.
Advances in experimental medicine and biology 2008;615():251-60.
2007: Xavier Leleu; Xiaoying Jia; Judith M Runnels; Hai T Ngo; Anne-Sophie Moreau; Mena Farag; Joel A Spencer; Costas M Pitsillides; Evdoxia Hatjiharissi; Aldo Roccaro; Garrett O'Sullivan; Douglas W McMillin; Daisy Moreno; Tanyel Kiziltepe; Ruben D Carrasco; Steve P Treon; Teru Hideshima; Kenneth C Anderson; Charles P Lin; Irene M Ghobrial
The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia.
Blood 2007;110(13):4417-26.
2007: klaus podar; Paul G Richardson; Teru Hideshima; Dharminder Chauhan; Kenneth C Anderson
The malignant clone and the bone-marrow environment.
Best practice & research. Clinical haematology 2007;20(4):597-612.
2007: Teru Hideshima; Kenneth C Anderson
Preclinical studies of novel targeted therapies.
Hematology/oncology clinics of North America 2007;21(6):1071-91, viii-ix.
2007: Constantine S Mitsiades; Douglas W McMillin; Steffen Klippel; Teru Hideshima; Dharminder Chauhan; Paul G Richardson; Nikhil C Munshi; Kenneth C Anderson
The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies.
Hematology/oncology clinics of North America 2007;21(6):1007-34, vii-viii.
2007: Paola Neri; Pierfrancesco Tassone; Masood Ahmad Shammas; Hiroshi Yasui; Ernestina Schipani; Ramesh Babu Batchu; Simona Blotta; Rao H Prabhala; Laurence Catley; Makoto Hamasaki; Teru Hideshima; Dharminder Chauhan; Gary S Jacob; Donald Picker; Salvatore Venuta; Kenneth C Anderson; Nikhil C Munshi
Biological pathways and in vivo antitumor activity induced by Atiprimod in myeloma.
Leukemia 2007;21(12):2519-26.
2007: Sonia Vallet; Noopur Raje; Kenji Ishitsuka; Teru Hideshima; klaus podar; Shweta Chhetri; Samantha Pozzi; Iris Breitkreutz; Tanyel Kiziltepe; Hiroshi Yasui; Enrique M Ocio; Norihiko Shiraishi; Janice Jin; Yutaka Okawa; Hiroshi Ikeda; Siddhartha Mukherjee; Nileshwari Vaghela; Diana Cirstea; marco ladetto; Mario Boccadoro; Kenneth C Anderson
MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts.
Blood 2007;110(10):3744-52.
2007: Paola Neri; Shaji Kumar; Mariateresa Fulciniti; Sonia Vallet; Shweta Chhetri; Sidhartha Mukherjee; Yu-Tzu Tai; Dharminder Chauhan; Pierfrancesco Tassone; Salvatore Venuta; Nikhil C Munshi; Teru Hideshima; Kenneth C Anderson; Noopur Raje
Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(19):5903-9.
2007: Iris Breitkreutz; Marc S Raab; Sonia Vallet; Teru Hideshima; Noopur Raje; Dharminder Chauhan; Nikhil C Munshi; Paul G Richardson; Kenneth C Anderson
Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma.
British journal of haematology 2007;139(1):55-63.
2007: Teru Hideshima; Laurence Catley; Noopur Raje; Dharminder Chauhan; klaus podar; Constantine S Mitsiades; Yu-Tzu Tai; Sonia Vallet; Tanyel Kiziltepe; Enrique M Ocio; Hiroshi Ikeda; Yutaka Okawa; Hiromasa Hideshima; Nikhil C Munshi; Hiroshi Yasui; Paul G Richardson; Kenneth C Anderson
Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells.
British journal of haematology 2007;138(6):783-91.
2007: Yu-Tzu Tai; Mariateresa Fulciniti; Teru Hideshima; Weihua Song; Merav Leiba; Xian-Feng Li; Matthew Rumizen; Peter C Burger; Aileen Morrison; klaus podar; Dharminder Chauhan; Pierfrancesco Tassone; Paul Richardson; Nikhil C Munshi; Irene M Ghobrial; Kenneth C Anderson
Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis.
Blood 2007;110(5):1656-63.
2007: Teru Hideshima; Constantine S Mitsiades; Giovanni Tonon; Paul G Richardson; Kenneth C Anderson
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets.
Nature reviews. Cancer 2007;7(8):585-98.
2007: Tanyel Kiziltepe; Teru Hideshima; Kenji Ishitsuka; Enrique M Ocio; Noopur Raje; Laurence Catley; Chun-Qi Li; Laura J Trudel; Hiroshi Yasui; Sonia Vallet; Jeffery L Kutok; Dharminder Chauhan; Constantine S Mitsiades; Joseph E Saavedra; Gerald N Wogan; Larry K Keefer; Paul J Shami; Kenneth C Anderson
JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells.
Blood 2007;110(2):709-18.
2007: Hashem Younes; Xavier Leleu; Evdoxia Hatjiharissi; Anne-Sophie Moreau; Teru Hideshima; Paul Richardson; Kenneth C Anderson; Irene M Ghobrial
Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(13):3771-5.
2007: Laurence Catley; Teru Hideshima; Dharminder Chauhan; Paola Neri; Pierfrancesco Tassone; Roderick Bronson; Weihua Song; Yu-Tzu Tai; Nikhil C Munshi; Kenneth C Anderson
Alkyl phospholipid perifosine induces myeloid hyperplasia in a murine myeloma model.
Experimental hematology 2007;35(7):1038-46.
2007: Joanne Ghobrial; Irene M Ghobrial; Constantine S Mitsiades; Xavier Leleu; Evdoxia Hatjiharissi; Anne-Sophie Moreau; Aldo Roccaro; Robert Schlossman; Teru Hideshima; Kenneth C Anderson; Paul Richardson
Novel therapeutic avenues in myeloma: changing the treatment paradigm.
Oncology (Williston Park, N.Y.) 2007;21(7):785-92; discussion 798-800.
2007: Tanyel Kiziltepe; Teru Hideshima; Laurence Catley; Noopur Raje; Hiroshi Yasui; Norihiko Shiraishi; Yutaka Okawa; Hiroshi Ikeda; Sonia Vallet; Samantha Pozzi; Kenji Ishitsuka; Enrique M Ocio; Dharminder Chauhan; Kenneth C Anderson
5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells.
Molecular cancer therapeutics 2007;6(6):1718-27.
2007: Anne-Sophie Moreau; Xiaoying Jia; Hai T Ngo; Xavier Leleu; Garrett O'Sullivan; Yazan Alsayed; Alexey A Leontovich; klaus podar; Jeffery L Kutok; John Daley; Suzan Lazo-Kallanian; Evdoxia Hatjiharissi; Marc S Raab; Lian Xu; Steve P Treon; Teru Hideshima; Kenneth C Anderson; Irene M Ghobrial
Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia.
Blood 2007;109(11):4964-72.
2007: Dharminder Chauhan; Mugdha Velankar; M Brahmandam; Teru Hideshima; klaus podar; Paul Richardson; Robert Schlossman; Irene M Ghobrial; Noopur Raje; Nikhil C Munshi; Kenneth C Anderson
A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma.
Oncogene 2007;26(16):2374-80.
2007: Yazan Alsayed; Hai T Ngo; Judith M Runnels; Xavier Leleu; Ujjal K Singha; Costas M Pitsillides; Joel A Spencer; Teresa Kimlinger; Joanna M Ghobrial; Xiaoying Jia; Ganwei Lu; Michael Timm; Ashok Kumar; Daniel Côté; Israel Veilleux; Karen E Hedin; David G Roodman; Thomas E Witzig; Andrew L Kung; Teru Hideshima; Kenneth C Anderson; Charles P Lin; Irene M Ghobrial
Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma.
Blood 2007;109(7):2708-17.
2007: Irene M Ghobrial; Xavier Leleu; Evdoxia Hatjiharissi; Teru Hideshima; Constantine S Mitsiades; Robert Schlossman; Kenneth C Anderson; Paul Richardson
Emerging drugs in multiple myeloma.
Expert opinion on emerging drugs 2007;12(1):155-63.
2007: Hiroshi Yasui; Teru Hideshima; H Ikeda; Enrique M Ocio; Tanyel Kiziltepe; Sonia Vallet; Y Okawa; Paola Neri; Kumar Sukhdeo; klaus podar; Dharminder Chauhan; Paul G Richardson; Noopur Raje; Daniel R Carrasco; Kenneth C Anderson
Novel etodolac analog SDX-308 (CEP-18082) induces cytotoxicity in multiple myeloma cells associated with inhibition of beta-catenin/TCF pathway.
Leukemia 2007;21(3):535-40.
2007: klaus podar; Marc S Raab; Giovanni Tonon; Martin Sattler; Daniela Barilà; Jing Zhang; Yu-Tzu Tai; Hiroshi Yasui; Noopur Raje; Ronald A DePinho; Teru Hideshima; Dharminder Chauhan; Kenneth C Anderson
Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma.
Cancer research 2007;67(4):1680-8.
2007: klaus podar; Marc S Raab; Jing Zhang; Douglas W McMillin; Iris Breitkreutz; Yu-Tzu Tai; Boris K Lin; Nikhil C Munshi; Teru Hideshima; Dharminder Chauhan; Kenneth C Anderson
Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl).
Blood 2007;109(4):1669-77.
2007: Paul G Richardson; Teru Hideshima; Constantine S Mitsiades; Kenneth C Anderson
The emerging role of novel therapies for the treatment of relapsed myeloma.
Journal of the National Comprehensive Cancer Network : JNCCN 2007;5(2):149-62.
2007: Hiroshi Yasui; Teru Hideshima; Hiroshi Ikeda; Janice Jin; Enrique M Ocio; Tanyel Kiziltepe; Yutaka Okawa; Sonia Vallet; klaus podar; Kenji Ishitsuka; Paul G Richardson; Christopher A Pargellis; Neil Moss; Noopur Raje; Kenneth C Anderson
BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth.
British journal of haematology 2007;136(3):414-23.
2007: Dharminder Chauhan; Paola Neri; Mugdha Velankar; klaus podar; Teru Hideshima; Mariateresa Fulciniti; Pierfrancesco Tassone; Noopur Raje; Constantine S Mitsiades; Nicholas Mitsiades; Paul Richardson; Leigh Zawel; Mary Tran; Nikhil C Munshi; Kenneth C Anderson
Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM).
Blood 2007;109(3):1220-7.
2007: Paul G Richardson; Constantine S Mitsiades; Robert Schlossman; Irene M Ghobrial; Teru Hideshima; Dharminder Chauhan; Nikhil C Munshi; Kenneth C Anderson
The treatment of relapsed and refractory multiple myeloma.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2007;():317-23.
2006: klaus podar; Giovanni Tonon; Martin Sattler; Yu-Tzu Tai; Steven Legouill; Hiroshi Yasui; Kenji Ishitsuka; Shaji Kumar; Rakesh Kumar; Lini Pandite; Teru Hideshima; Dharminder Chauhan; Kenneth C Anderson
The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(51):19478-83.
2006: Hiroshi Yasui; Teru Hideshima; Kenneth C Anderson
Non-steroidal anti-inflammatory drug therapy for chronic lymphocytic leukemia.
Leukemia & lymphoma 2006;47(12):2445-6.
2006: Lanie K Francis; Yazan Alsayed; Xavier Leleu; Xiaoying Jia; Ujjal K Singha; Judith Anderson; Michael Timm; Hai T Ngo; Ganwei Lu; Alissa Huston; Lori A Ehrlich; Elizabeth Dimmock; Suzanne Lentzsch; Teru Hideshima; David G Roodman; Kenneth C Anderson; Irene M Ghobrial
Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(22):6826-35.
2006: Paul G Richardson; Emily Blood; Constantine S Mitsiades; Sundar Jagannath; Steven R Zeldenrust; Melissa Alsina; Robert Schlossman; S Vincent Rajkumar; K Raman Desikan; Teru Hideshima; Nikhil C Munshi; Kathleen Kelly-Colson; Deborah Doss; Mary L McKenney; Svetlana Gorelik; Diane Warren; Andrea Freeman; Rebecca Rich; Anfang Wu; Marta Olesnyckyj; Kenton Wride; William S Dalton; Jerome B Zeldis; Robert Knight; Edie Weller; Kenneth C Anderson
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Blood 2006;108(10):3458-64.
2006: Laurence Catley; Ellen Weisberg; Tanyel Kiziltepe; Yu-Tzu Tai; Teru Hideshima; Paola Neri; Pierfrancesco Tassone; Peter Atadja; Dharminder Chauhan; Nikhil C Munshi; Kenneth C Anderson
Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells.
Blood 2006;108(10):3441-9.
2006: Dharminder Chauhan; Teru Hideshima; Kenneth C Anderson
A novel proteasome inhibitor NPI-0052 as an anticancer therapy.
British journal of cancer 2006;95(8):961-5.
2006: Hiroshi Yasui; Teru Hideshima; Paul G Richardson; Kenneth C Anderson
Recent advances in the treatment of Multiple Myeloma.
Current pharmaceutical biotechnology 2006;7(5):381-93.
2006: Constantine S Mitsiades; Nicholas Mitsiades; Teru Hideshima; Paul G Richardson; Kenneth C Anderson
Proteasome inhibition as a new therapeutic principle in hematological malignancies.
Current drug targets 2006;7(10):1341-7.
2006: Teru Hideshima; Paola Neri; Pierfrancesco Tassone; Hiroshi Yasui; Kenji Ishitsuka; Noopur Raje; Dharminder Chauhan; klaus podar; Constantine S Mitsiades; Lenny Dang; Nikhil C Munshi; Paul Richardson; David P Schenkein; Kenneth C Anderson
MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(19):5887-94.
2006: Noopur Raje; Shaji Kumar; Teru Hideshima; Kenji Ishitsuka; Hiroshi Yasui; Shweta Chhetri; Sonia Vallet; E Vonescu; Norihiko Shiraishi; Tanyel Kiziltepe; H L Elford; Nikhil C Munshi; Kenneth C Anderson
Didox, a ribonucleotide reductase inhibitor, induces apoptosis and inhibits DNA repair in multiple myeloma cells.
British journal of haematology 2006;135(1):52-61.
2006: Noopur Raje; Teru Hideshima; Kenneth C Anderson
Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma.
Expert review of anticancer therapy 2006;6(9):1239-47.
2006: Paul G Richardson; Constantine S Mitsiades; Teru Hideshima; Kenneth C Anderson
Lenalidomide in multiple myeloma.
Expert review of anticancer therapy 2006;6(8):1165-73.
2006: Hiroshi Yasui; Teru Hideshima
[Proteasome inhibitor bortezomib as an anticancer drug].
Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme 2006;51(10 Suppl):1251-6.
2006: Reshma Shringarpure; Laurence Catley; Deepak Bhole; Renate Burger; klaus podar; Yu-Tzu Tai; Benedikt Kessler; Paul J Galardy; Hidde L Ploegh; Pierfrancesco Tassone; Teru Hideshima; Constantine S Mitsiades; Nikhil C Munshi; Dharminder Chauhan; Kenneth C Anderson
Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib.
British journal of haematology 2006;134(2):145-56.
2006: Yu-Tzu Tai; Xian-Feng Li; Iris Breitkreutz; Weihua Song; Paola Neri; Laurence Catley; klaus podar; Teru Hideshima; Dharminder Chauhan; Noopur Raje; Robert Schlossman; Paul Richardson; Nikhil C Munshi; Kenneth C Anderson
Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.
Cancer research 2006;66(13):6675-82.
2006: Paola Neri; Hiroshi Yasui; Teru Hideshima; Pierfrancesco Tassone; Noopur Raje; Laurence Catley; Catley P Laurence; Kenji Ishitsuka; Simona Blotta; Tanyel Kiziltepe; Enrique M Ocio; Mariateresa Fulciniti; Sarath Kanekal; Gary T Elliott; Nikhil C Munshi; Kenneth C Anderson
In vivo and in vitro cytotoxicity of R-etodolac with dexamethasone in glucocorticoid-resistant multiple myeloma cells.
British journal of haematology 2006;134(1):37-44.
2006: Tony A Navas; Aaron N Nguyen; Teru Hideshima; Mamatha Reddy; Jing Ying Ma; Edwin Haghnazari; Margaret Henson; Elizabeth G Stebbins; Irene Kerr; Gilbert O'Young; Ann M Kapoun; Sarvajit Chakravarty; Babu J Mavunkel; John J Perumattam; Gregory R Luedtke; Sundeep Dugar; Satyanarayana Medicherla; Protter Andrew; George F Schreiner; Kenneth C Anderson; Linda S Higgins
Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo.
Leukemia 2006;20(6):1017-27.
2006: Teru Hideshima; Laurence Catley; Hiroshi Yasui; Kenji Ishitsuka; Noopur Raje; Constantine S Mitsiades; klaus podar; Nikhil C Munshi; Dharminder Chauhan; Paul G Richardson; Kenneth C Anderson
Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells.
Blood 2006;107(10):4053-62.
2006: Shaji Kumar; Noopur Raje; Teru Hideshima; Kenji Ishitsuka; klaus podar; Steven Le Gouille; Dharminder Chauhan; Paul Richardson; Nikhil C Munshi; Kenneth C Anderson
FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myeloma.
British journal of haematology 2006;132(6):698-704.
2006: Teru Hideshima; Paul G Richardson; Kenneth C Anderson
Current therapeutic uses of lenalidomide in multiple myeloma.
Expert opinion on investigational drugs 2006;15(2):171-9.
2006: Hiroshi Yasui; Teru Hideshima; Paul G Richardson; Kenneth C Anderson
Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma.
British journal of haematology 2006;132(4):385-97.
2006: Constantine S Mitsiades; Nicholas Mitsiades; Ciaran McMullan; Vassiliki Poulaki; Andrew L Kung; Faith E Davies; Gareth Morgan; Masaharu Akiyama; Reshma Shringarpure; Nikhil C Munshi; Paul G Richardson; Teru Hideshima; Dharminder Chauhan; Xuesong Gu; Charles Bailey; Marie Joseph; Towia Libermann; Neal Rosen; Kenneth C Anderson
Antimyeloma activity of heat shock protein-90 inhibition.
Blood 2006;107(3):1092-100.
2006: Paul G Richardson; Constantine S Mitsiades; Teru Hideshima; Kenneth C Anderson
Bortezomib: proteasome inhibition as an effective anticancer therapy.
Annual review of medicine 2006;57():33-47.
2006: Aldo Roccaro; Teru Hideshima; Noopur Raje; Shaji Kumar; Kenji Ishitsuka; Hiroshi Yasui; Norihiko Shiraishi; Dragana Vukasovic; Beatrice Nico; Angelo Vacca; Franco Dammacco; Paul G Richardson; Kenneth C Anderson
Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells.
Cancer research 2006;66(1):184-91.
2005: Teru Hideshima; James E Bradner; Dharminder Chauhan; Kenneth C Anderson
Intracellular protein degradation and its therapeutic implications.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(24 Pt 1):8530-3.
2005: Yu-Tzu Tai; Xian-Feng Li; Laurence Catley; Rory Coffey; Iris Breitkreutz; Jooeun Bae; Weihua Song; klaus podar; Teru Hideshima; Dharminder Chauhan; Robert Schlossman; Paul Richardson; Steve P Treon; Iqbal Grewal; Nikhil C Munshi; Kenneth C Anderson
Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications.
Cancer research 2005;65(24):11712-20.
2005: Paul G Richardson; Robert Schlossman; Teru Hideshima; Kenneth C Anderson
New treatments for multiple myeloma.
Oncology (Williston Park, N.Y.) 2005;19(14):1781-92; discussion 1792, 1795-7.
2005: Dharminder Chauhan; Laurence Catley; Guilan Li; klaus podar; Teru Hideshima; Mugdha Velankar; Constantine S Mitsiades; Nicholas Mitsiades; Hiroshi Yasui; Anthony Letai; Huib Ovaa; Celia R Berkers; Benjamin Nicholson; Ta-Hsiang Chao; Saskia T C Neuteboom; Paul Richardson; Michael A Palladino; Kenneth C Anderson
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib.
Cancer cell 2005;8(5):407-19.
2005: Paul G Richardson; Bart Barlogie; James Berenson; shashank singhal; Sundar Jagannath; David Irwin; S Vincent Rajkumar; Teru Hideshima; Hugh Xiao; Dixie Esseltine; David P Schenkein; Kenneth C Anderson
Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma.
Blood 2005;106(9):2977-81.
2005: Dharminder Chauhan; Guilan Li; klaus podar; Teru Hideshima; Paola Neri; Deli He; Nicholas Mitsiades; Paul Richardson; Yan Chang; Joanne Schindler; Bradley Carver; Kenneth C Anderson
A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
Cancer research 2005;65(18):8350-8.
2005: Teru Hideshima; Dharminder Chauhan; Paul Richardson; Kenneth C Anderson
Identification and validation of novel therapeutic targets for multiple myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(26):6345-50.
2005: Paul G Richardson; Robert Schlossman; Constantine S Mitsiades; Teru Hideshima; Nikhil C Munshi; Kenneth C Anderson
Emerging trends in the clinical use of bortezomib in multiple myeloma.
Clinical lymphoma & myeloma 2005;6(2):84-8.
2005: Mikael Altun; Paul J Galardy; Reshma Shringarpure; Teru Hideshima; Richard LeBlanc; Kenneth C Anderson; Hidde L Ploegh; Benedikt M Kessler
Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells.
Cancer research 2005;65(17):7896-901.
2005: Kenji Ishitsuka; Teru Hideshima; Makoto Hamasaki; Noopur Raje; Shaji Kumar; klaus podar; Steven Le Gouill; Norihiko Shiraishi; Hiroshi Yasui; Aldo Roccaro; Yu-Zu Tai; Dharminder Chauhan; Robert Fram; Kazuo Tamura; Jugnu Jain; Kenneth C Anderson
Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway.
Oncogene 2005;24(38):5888-96.
2005: Kenji Ishitsuka; Teru Hideshima; Makoto Hamasaki; Noopur Raje; Shaji Kumar; Hiromasa Hideshima; Norihiko Shiraishi; Hiroshi Yasui; Aldo Roccaro; Paul Richardson; klaus podar; Steven Le Gouill; Dharminder Chauhan; Kazuo Tamura; Jack Arbiser; Kenneth C Anderson
Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis.
Blood 2005;106(5):1794-800.
2005: Hiroshi Yasui; Teru Hideshima; Noopur Raje; Aldo Roccaro; Norihiko Shiraishi; Shaji Kumar; Makoto Hamasaki; Kenji Ishitsuka; Yu-Tzu Tai; klaus podar; Laurence Catley; Constantine S Mitsiades; Paul G Richardson; Rainer Albert; Volker Brinkmann; Dharminder Chauhan; Kenneth C Anderson
FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance.
Cancer research 2005;65(16):7478-84.
2005: Noopur Raje; Shaji Kumar; Teru Hideshima; Aldo Roccaro; Kenji Ishitsuka; Hiroshi Yasui; Norihiko Shiraishi; Dharminder Chauhan; Nikhil C Munshi; Simon R Green; Kenneth C Anderson
Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma.
Blood 2005;106(3):1042-7.
2005: Hiroshi Yasui; Teru Hideshima; Makoto Hamasaki; Aldo Roccaro; Norihiko Shiraishi; Shaji Kumar; Pierfrancesco Tassone; Kenji Ishitsuka; Noopur Raje; Yu-Tzu Tai; klaus podar; Dharminder Chauhan; Lorenzo Leoni; Sarath Kanekal; Gary Elliott; Nikhil C Munshi; Kenneth C Anderson
SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma.
Blood 2005;106(2):706-12.
2005: Yu-Tzu Tai; Xianfeng Li; Xia Tong; Daniel Santos; Takemi Otsuki; Laurence Catley; Olivier Tournilhac; klaus podar; Teru Hideshima; Robert Schlossman; Paul Richardson; Nikhil C Munshi; Mohammad Luqman; Kenneth C Anderson
Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma.
Cancer research 2005;65(13):5898-906.
2005: Shaji Kumar; Noopur Raje; Teru Hideshima; Kenji Ishitsuka; Aldo Roccaro; Norihiko Shiraishi; Makoto Hamasaki; Hiroshi Yasui; Nikhil C Munshi; Paul Richardson; W D Figg; Kenneth C Anderson
Antimyeloma activity of two novel N-substituted and tetraflourinated thalidomide analogs.
Leukemia 2005;19(7):1253-61.
2005: Teru Hideshima; James E Bradner; Jason Wong; Dharminder Chauhan; Paul Richardson; Stuart L Schreiber; Kenneth C Anderson
Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(24):8567-72.
2005: Constantine S Mitsiades; Nicholas Mitsiades; Teru Hideshima; Paul G Richardson; Kenneth C Anderson
Proteasome inhibition as a therapeutic strategy for hematologic malignancies.
Expert review of anticancer therapy 2005;5(3):465-76.
2005: Makoto Hamasaki; Teru Hideshima; Pierfrancesco Tassone; Paola Neri; Kenji Ishitsuka; Hiroshi Yasui; Norihiko Shiraishi; Noopur Raje; Shaji Kumar; Donald Picker; Gary S Jacob; Paul G Richardson; Nikhil C Munshi; Kenneth C Anderson
Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo.
Blood 2005;105(11):4470-6.
2005: Teru Hideshima; Dharminder Chauhan; Kenji Ishitsuka; Hiroshi Yasui; Noopur Raje; Shaji Kumar; klaus podar; Constantine S Mitsiades; Hiromasa Hideshima; Lynn Bonham; Nikhil C Munshi; Paul G Richardson; Jack W Singer; Kenneth C Anderson
Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors.
Oncogene 2005;24(19):3121-9.
2005: klaus podar; Teru Hideshima; Dharminder Chauhan; Kenneth C Anderson
Targeting signalling pathways for the treatment of multiple myeloma.
Expert opinion on therapeutic targets 2005;9(2):359-81.
2005: Dharminder Chauhan; Teru Hideshima; Constantine S Mitsiades; Paul Richardson; Kenneth C Anderson
Proteasome inhibitor therapy in multiple myeloma.
Molecular cancer therapeutics 2005;4(4):686-92.
2005: Paul G Richardson; Constantine S Mitsiades; Teru Hideshima; Kenneth C Anderson
Proteasome inhibition in the treatment of cancer.
Cell cycle (Georgetown, Tex.) 2005;4(2):290-6.
2005: S Vincent Rajkumar; Paul G Richardson; Teru Hideshima; Kenneth C Anderson
Proteasome inhibition as a novel therapeutic target in human cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(3):630-9.
2005: Constantine S Mitsiades; Nicholas Mitsiades; Teru Hideshima; Paul G Richardson; Kenneth C Anderson
Proteasome inhibitors as therapeutics.
Essays in biochemistry 2005;41():205-18.
2005: Paul G Richardson; Constantine S Mitsiades; Teru Hideshima; Kenneth C Anderson
Novel biological therapies for the treatment of multiple myeloma.
Best practice & research. Clinical haematology 2005;18(4):619-34.
2005: Teru Hideshima; klaus podar; Dharminder Chauhan; Kenneth C Anderson
Cytokines and signal transduction.
Best practice & research. Clinical haematology 2005;18(4):509-24.
2005: Dharminder Chauhan; Teru Hideshima; Kenneth C Anderson
Proteasome inhibition in multiple myeloma: therapeutic implication.
Annual review of pharmacology and toxicology 2005;45():465-76.
2005: Toshiaki Hayashi; Teru Hideshima; Masaharu Akiyama; klaus podar; Hiroshi Yasui; Noopur Raje; Shaji Kumar; Dharminder Chauhan; Steve P Treon; Paul G Richardson; Kenneth C Anderson
Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.
British journal of haematology 2005;128(2):192-203.
2004: Noopur Raje; Shaji Kumar; Teru Hideshima; Kenji Ishitsuka; Dharminder Chauhan; Constantine S Mitsiades; klaus podar; Steven Le Gouill; Paul Richardson; Nikhil C Munshi; David I Stirling; Joseph H Antin; Kenneth C Anderson
Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma.
Blood 2004;104(13):4188-93.
2004: Laurence Catley; Yu-Tzu Tai; Reshma Shringarpure; Renate Burger; Moni Thi Son; klaus podar; Pierfrancesco Tassone; Dharminder Chauhan; Teru Hideshima; Louis Denis; Paul Richardson; Nikhil C Munshi; Kenneth C Anderson
Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma.
Cancer research 2004;64(23):8746-53.
2004: Pierfrancesco Tassone; Victor S Goldmacher; Paola Neri; Antonella Gozzini; Masood Ahmad Shammas; Kathleen R Whiteman; Linda L Hylander-Gans; Daniel R Carrasco; Teru Hideshima; Reshma Shringarpure; Jialan Shi; Charles K Allam; John Wijdenes; Salvatore Venuta; Nikhil C Munshi; Kenneth C Anderson
Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells.
Blood 2004;104(12):3688-96.
2004: Teru Hideshima; klaus podar; Dharminder Chauhan; Kenji Ishitsuka; Constantine S Mitsiades; Yu-Tzu Tai; Makoto Hamasaki; Noopur Raje; Hiromasa Hideshima; George F Schreiner; Aaron N Nguyen; Tony A Navas; Nikhil C Munshi; Paul G Richardson; Linda S Higgins; Kenneth C Anderson
p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells.
Oncogene 2004;23(54):8766-76.
2004: Toshiaki Hayashi; Teru Hideshima; Aaron N Nguyen; Olivier Munoz; klaus podar; Makoto Hamasaki; Kenji Ishitsuka; Hiroshi Yasui; Paul Richardson; Sarvajit Chakravarty; Alison Murphy; Dharminder Chauhan; Linda S Higgins; Kenneth C Anderson
Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(22):7540-6.
2004: Steven Le Gouill; klaus podar; Martine Amiot; Teru Hideshima; Dharminder Chauhan; Kenji Ishitsuka; Shaji Kumar; Noopur Raje; Paul G Richardson; Jean-Luc Harousseau; Kenneth C Anderson
VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis.
Blood 2004;104(9):2886-92.
2004: klaus podar; Reshma Shringarpure; Yu-Tzu Tai; Melissa Simoncini; Martin Sattler; Kenji Ishitsuka; Paul G Richardson; Teru Hideshima; Dharminder Chauhan; Kenneth C Anderson
Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib.
Cancer research 2004;64(20):7500-6.
2004: Dharminder Chauhan; Guilan Li; klaus podar; Teru Hideshima; Constantine S Mitsiades; Robert Schlossman; Nikhil C Munshi; Paul Richardson; Finbarr E Cotter; Kenneth C Anderson
Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells.
Blood 2004;104(8):2458-66.
2004: Teru Hideshima; P Leif Bergsagel; W Michael Kuehl; Kenneth C Anderson
Advances in biology of multiple myeloma: clinical applications.
Blood 2004;104(3):607-18.
2004: Paul Richardson; Robert Schlossman; Sundar Jagannath; Melissa Alsina; Raman Desikan; Emily Blood; Edie Weller; Constantine S Mitsiades; Teru Hideshima; Faith Davies; Deborah Doss; Andrea Freeman; Joan Bosch; John Patin; Robert Knight; Jerome B Zeldis; William Dalton; Kenneth C Anderson
Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity.
Mayo Clinic proceedings. Mayo Clinic 2004;79(7):875-82.
2004: Paul Richardson; Teru Hideshima; Kenneth C Anderson
An update of novel therapeutic approaches for multiple myeloma.
Current treatment options in oncology 2004;5(3):227-38.
2004: klaus podar; Gustavo Mostoslavsky; Martin Sattler; Yu-Tzu Tai; Toshiaki Hayashi; Laurence Catley; Teru Hideshima; Richard C Mulligan; Dharminder Chauhan; Kenneth C Anderson
Critical role for hematopoietic cell kinase (Hck)-mediated phosphorylation of Gab1 and Gab2 docking proteins in interleukin 6-induced proliferation and survival of multiple myeloma cells.
The Journal of biological chemistry 2004;279(20):21658-65.
2004: Noopur Raje; Teru Hideshima; Faith E Davies; Dharminder Chauhan; Steve P Treon; Gloria Young; Yu-Tzu Tai; David Avigan; Jianlin Gong; Robert Schlossman; Paul Richardson; Donald Kufe; Kenneth C Anderson
Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma.
British journal of haematology 2004;125(3):343-52.
2004: klaus podar; Laurence Catley; Yu-Tzu Tai; Reshma Shringarpure; Pedro Carvalho; Toshiaki Hayashi; Renate Burger; Robert Schlossman; Paul G Richardson; Lini Pandite; Rakesh Kumar; Teru Hideshima; Dharminder Chauhan; Kenneth C Anderson
GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment.
Blood 2004;103(9):3474-9.
2004: Dharminder Chauhan; Guilan Li; Teru Hideshima; klaus podar; Reshma Shringarpure; Constantine S Mitsiades; Nikhil C Munshi; Patricia Yew; Kenneth C Anderson
Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341.
Oncogene 2004;23(20):3597-602.
2004: Yu-Tzu Tai; Laurence Catley; Constantine S Mitsiades; Renate Burger; klaus podar; Reshma Shringpaure; Teru Hideshima; Dharminder Chauhan; Makoto Hamasaki; Kenji Ishitsuka; Paul Richardson; Steve P Treon; Nikhil C Munshi; Kenneth C Anderson
Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications.
Cancer research 2004;64(8):2846-52.
2004: Dharminder Chauhan; Guilan Li; klaus podar; Teru Hideshima; Reshma Shringarpure; Laurence Catley; Constantine S Mitsiades; Nikhil C Munshi; Yu-Tzu Tai; Nanjoo Suh; Gordon W Gribble; Tadashi Honda; Robert Schlossman; Paul Richardson; Michael B. Sporn; Kenneth C Anderson
The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance.
Blood 2004;103(8):3158-66.
2004: Masaharu Akiyama; Osamu Yamada; Teru Hideshima; Takaaki Yanagisawa; Kentaro Yokoi; Kohji Fujisawa; Yoshikatsu Eto; Hisashi Yamada; Kenneth C Anderson
TNFalpha induces rapid activation and nuclear translocation of telomerase in human lymphocytes.
Biochemical and biophysical research communications 2004;316(2):528-32.
2004: Constantine S Mitsiades; Nicholas Mitsiades; Ciaran McMullan; Vassiliki Poulaki; Reshma Shringarpure; Masaharu Akiyama; Teru Hideshima; Dharminder Chauhan; Marie Joseph; Towia Libermann; Carlos García-Echeverría; Mark A Pearson; Francesco Hofmann; Kenneth C Anderson; Andrew L Kung
Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors.
Cancer cell 2004;5(3):221-30.
2004: Dharminder Chauhan; Guilan Li; Daniel Auclair; Teru Hideshima; klaus podar; Nicholas Mitsiades; Constantine S Mitsiades; Lan Bo Chen; Nikhil C Munshi; S Saxena; Kenneth C Anderson
2-Methoxyestardiol and bortezomib/proteasome-inhibitor overcome dexamethasone-resistance in multiple myeloma cells by modulating Heat Shock Protein-27.
Apoptosis : an international journal on programmed cell death 2004;9(2):149-55.
2004: Richard LeBlanc; Teru Hideshima; Laurence Catley; Reshma Shringarpure; Renate Burger; Nicholas Mitsiades; Constantine S Mitsiades; Puneet Cheema; Dharminder Chauhan; Paul G Richardson; Kenneth C Anderson; Nikhil C Munshi
Immunomodulatory drug costimulates T cells via the B7-CD28 pathway.
Blood 2004;103(5):1787-90.
2004: Nikhil C Munshi; Teru Hideshima; Daniel R Carrasco; Masood Ahmad Shammas; Daniel Auclair; Faith Davies; Nicholas Mitsiades; Constantine S Mitsiades; Ryung S. Kim; Cheng Li; S Vincent Rajkumar; Rafael Fonseca; Lief Bergsagel; Dharminder Chauhan; Kenneth C Anderson
Identification of genes modulated in multiple myeloma using genetically identical twin samples.
Blood 2004;103(5):1799-806.
2004: Constantine S Mitsiades; Nicholas Mitsiades; Ciaran McMullan; Vassiliki Poulaki; Reshma Shringarpure; Teru Hideshima; Masaharu Akiyama; Dharminder Chauhan; Nikhil C Munshi; Xuesong Gu; Charles Bailey; Marie Joseph; Towia Libermann; Victoria M Richon; Paul A Marks; Kenneth C Anderson
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(2):540-5.
2004: Paul G Richardson; Teru Hideshima; Constantine S Mitsiades; Kenneth C Anderson
Proteasome inhibition in hematologic malignancies.
Annals of medicine 2004;36(4):304-14.
2003: Faith E Davies; Ann M Dring; Cheng Li; Andy C Rawstron; Masood Ahmad Shammas; Sheila M O'Connor; James A L Fenton; Teru Hideshima; Dharminder Chauhan; Isabella T Tai; Elizabeth Robinson; Daniel Auclair; Karen Rees; David Gonzalez; A John Ashcroft; Ranjit DasGupta; Constantine S Mitsiades; Nicholas Mitsiades; Lan Bo Chen; Wing H Wong; Nikhil C Munshi; Gareth J Morgan; Kenneth C Anderson
Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis.
Blood 2003;102(13):4504-11.
2003: Teru Hideshima; Dharminder Chauhan; Toshiaki Hayashi; klaus podar; Masaharu Akiyama; Constantine S Mitsiades; Nicholas Mitsiades; Baoqing Gong; Lynn Bonham; Peter de Vries; Nikhil C Munshi; Paul G Richardson; Jack W Singer; Kenneth C Anderson
Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma.
Cancer research 2003;63(23):8428-36.
2003: Renate Burger; Frank Bakker; Andreas Guenther; Wolfgang Baum; Dirk Schmidt-Arras; Teru Hideshima; Yu-Tzu Tai; Reshma Shringarpure; Laurence Catley; Giorgio Senaldi; Martin Gramatzki; Kenneth C Anderson
Functional significance of novel neurotrophin-1/B cell-stimulating factor-3 (cardiotrophin-like cytokine) for human myeloma cell growth and survival.
British journal of haematology 2003;123(5):869-78.
2003: Teru Hideshima; Toshiaki Hayashi; Dharminder Chauhan; Masaharu Akiyama; Paul Richardson; Kenneth C Anderson
Biologic sequelae of c-Jun NH(2)-terminal kinase (JNK) activation in multiple myeloma cell lines.
Oncogene 2003;22(54):8797-801.
2003: Teru Hideshima; Dharminder Chauhan; Toshiaki Hayashi; Masaharu Akiyama; Nicholas Mitsiades; Constantine S Mitsiades; klaus podar; Nikhil C Munshi; Paul G Richardson; Kenneth C Anderson
Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma.
Oncogene 2003;22(52):8386-93.
2003: Dharminder Chauhan; Guilan Li; Teru Hideshima; klaus podar; Constantine S Mitsiades; Nicholas Mitsiades; Laurence Catley; Yu-Tzu Tai; Toshiaki Hayashi; Reshma Shringarpure; Renate Burger; Nikhil C Munshi; Yasuyuki Ohtake; Satya Saxena; Kenneth C Anderson
Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance.
Blood 2003;102(9):3379-86.
2003: Constantine S Mitsiades; Nicholas Mitsiades; Ron T Bronson; Dharminder Chauhan; Nikhil C Munshi; Steve P Treon; Christopher A Maxwell; Linda M Pilarski; Teru Hideshima; Robert M Hoffman; Kenneth C Anderson
Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications.
Cancer research 2003;63(20):6689-96.
2003: Masaharu Akiyama; Teru Hideshima; Masood Ahmad Shammas; Toshiaki Hayashi; Makoto Hamasaki; Yu-Tzu Tai; Paul Richardson; Sergei Gryaznov; Nikhil C Munshi; Kenneth C Anderson
Effects of oligonucleotide N3'-->P5' thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells.
Cancer research 2003;63(19):6187-94.
2003: Dharminder Chauhan; Guilan Li; Reshma Shringarpure; klaus podar; Yasuyuki Ohtake; Teru Hideshima; Kenneth C Anderson
Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells.
Cancer research 2003;63(19):6174-7.
2003: Laurence Catley; Ellen Weisberg; Yu-Tzu Tai; Peter Atadja; Stacy W Remiszewski; Teru Hideshima; Nicholas Mitsiades; Reshma Shringarpure; Richard LeBlanc; Dharminder Chauhan; Nikhil C Munshi; Robert Schlossman; Paul Richardson; James Griffin; Kenneth C Anderson
NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma.
Blood 2003;102(7):2615-22.
2003: Dharminder Chauhan; Guilan Li; Martin Sattler; klaus podar; Constantine S Mitsiades; Nicholas Mitsiades; Nikhil C Munshi; Teru Hideshima; Kenneth C Anderson
Superoxide-dependent and -independent mitochondrial signaling during apoptosis in multiple myeloma cells.
Oncogene 2003;22(40):6296-300.
2003: Yu-Tzu Tai; klaus podar; Laurence Catley; Yu-Hua Tseng; Masaharu Akiyama; Reshma Shringarpure; Renate Burger; Teru Hideshima; Dharminder Chauhan; Nicholas Mitsiades; Paul Richardson; Nikhil C Munshi; C Ronald Kahn; Constantine S Mitsiades; Kenneth C Anderson
Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling.
Cancer research 2003;63(18):5850-8.
2003: Paul G Richardson; Teru Hideshima; Kenneth C Anderson
Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers.
Cancer control : journal of the Moffitt Cancer Center 2003;10(5):361-9.
2003: Masood Ahmad Shammas; Robert J Shmookler Reis; Masaharu Akiyama; Hemanta Koley; Dharminder Chauhan; Teru Hideshima; Raj K Goyal; Laurence H Hurley; Kenneth C Anderson; Nikhil C Munshi
Telomerase inhibition and cell growth arrest by G-quadruplex interactive agent in multiple myeloma.
Molecular cancer therapeutics 2003;2(9):825-33.
2003: Toshiaki Hayashi; Teru Hideshima; Masaharu Akiyama; Noopur Raje; Paul Richardson; Dharminder Chauhan; Kenneth C Anderson
Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes.
Blood 2003;102(4):1435-42.
2003: Dharminder Chauhan; Teru Hideshima; Kenneth C Anderson
Apoptotic signaling in multiple myeloma: therapeutic implications.
International journal of hematology 2003;78(2):114-20.
2003: Teru Hideshima; Paul Richardson; Kenneth C Anderson
Novel therapeutic approaches for multiple myeloma.
Immunological reviews 2003;194():164-76.
2003: Paul G Richardson; Bart Barlogie; James Berenson; shashank singhal; Sundar Jagannath; David Irwin; S Vincent Rajkumar; Gordan Srkalovic; Melissa Alsina; Raymond Alexanian; David Siegel; Robert Z Orlowski; David Kuter; Steven A Limentani; Stephanie Lee; Teru Hideshima; Dixie Esseltine; Michael Kauffman; Julian Adams; David P Schenkein; Kenneth C Anderson
A phase 2 study of bortezomib in relapsed, refractory myeloma.
The New England journal of medicine 2003;348(26):2609-17.
2003: Teru Hideshima; Paul G Richardson; Kenneth C Anderson
Targeting proteasome inhibition in hematologic malignancies.
Reviews in clinical and experimental hematology 2003;7(2):191-204.
2003: Dharminder Chauhan; Guilan Li; Teru Hideshima; klaus podar; Constantine S Mitsiades; Nicholas Mitsiades; Nikhil C Munshi; Surender Kharbanda; Kenneth C Anderson
JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cells.
The Journal of biological chemistry 2003;278(20):17593-6.
2003: Nicholas Mitsiades; Constantine S Mitsiades; Paul G Richardson; Ciaran McMullan; Vassiliki Poulaki; Galinos Fanourakis; Robert Schlossman; Dharminder Chauhan; Nikhil C Munshi; Teru Hideshima; Victoria M Richon; Paul A Marks; Kenneth C Anderson
Molecular sequelae of histone deacetylase inhibition in human malignant B cells.
Blood 2003;101(10):4055-62.
2003: Toshiaki Hayashi; Steve P Treon; Teru Hideshima; Yu-Tzu Tai; Masaharu Akiyama; Paul Richardson; Dharminder Chauhan; Iqbal Grewal; Kenneth C Anderson
Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells.
British journal of haematology 2003;121(4):592-6.
2003: Dharminder Chauhan; Guilan Li; Daniel Auclair; Teru Hideshima; Paul Richardson; klaus podar; Nicholas Mitsiades; Constantine S Mitsiades; Cheng Li; Ryung S. Kim; Nikhil C Munshi; Lan Bo Chen; Wing Wong; Kenneth C Anderson
Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays.
Blood 2003;101(9):3606-14.
2003: Stephanie Greenstein; Nancy L Krett; Yoshihiro Kurosawa; Chunguang Ma; Dharminder Chauhan; Teru Hideshima; Kenneth C Anderson; Steven T Rosen
Characterization of the MM.1 human multiple myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells.
Experimental hematology 2003;31(4):271-82.
2003: Yu-Tzu Tai; klaus podar; Nicholas Mitsiades; Boris Lin; Constantine S Mitsiades; Deepak Gupta; Masaharu Akiyama; Laurence Catley; Teru Hideshima; Nikhil C Munshi; Steve P Treon; Kenneth C Anderson
CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling.
Blood 2003;101(7):2762-9.
2003: Nicholas Mitsiades; Constantine S Mitsiades; Paul G Richardson; Vassiliki Poulaki; Yu-Tzu Tai; Dharminder Chauhan; Galinos Fanourakis; Xuesong Gu; Charles Bailey; Marie Joseph; Towia Libermann; Robert Schlossman; Nikhil C Munshi; Teru Hideshima; Kenneth C Anderson
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications.
Blood 2003;101(6):2377-80.
2003: klaus podar; Yu-Tzu Tai; Craig E Cole; Teru Hideshima; Martin Sattler; Angela Hamblin; Nicholas Mitsiades; Robert Schlossman; Faith E Davies; Gareth J Morgan; Nikhil C Munshi; Dharminder Chauhan; Kenneth C Anderson
Essential role of caveolae in interleukin-6- and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cells.
The Journal of biological chemistry 2003;278(8):5794-801.
2003: Teru Hideshima; Constantine S Mitsiades; Masaharu Akiyama; Toshiaki Hayashi; Dharminder Chauhan; Paul Richardson; Robert Schlossman; klaus podar; Nikhil C Munshi; Nicholas Mitsiades; Kenneth C Anderson
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.
Blood 2003;101(4):1530-4.
2003: Teru Hideshima; Masaharu Akiyama; Toshiaki Hayashi; Paul Richardson; Robert Schlossman; Dharminder Chauhan; Kenneth C Anderson
Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu.
Blood 2003;101(2):703-5.
2003: Suzanne Lentzsch; Richard LeBlanc; klaus podar; Faith Davies; Boris Lin; Teru Hideshima; Laurence Catley; David I Stirling; Kenneth C Anderson
Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo.
Leukemia 2003;17(1):41-4.
2003: Masaharu Akiyama; Teru Hideshima; Toshiaki Hayashi; Yu-Tzu Tai; Constantine S Mitsiades; Nicholas Mitsiades; Dharminder Chauhan; Paul Richardson; Nikhil C Munshi; Kenneth C Anderson
Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein.
Cancer research 2003;63(1):18-21.
2003: Toshiaki Hayashi; Teru Hideshima; Kenneth C Anderson
Novel therapies for multiple myeloma.
British journal of haematology 2003;120(1):10-7.
2002: Teru Hideshima; Kenneth C Anderson
Molecular mechanisms of novel therapeutic approaches for multiple myeloma.
Nature reviews. Cancer 2002;2(12):927-37.
2002: Paul G Richardson; Robert Schlossman; Edie Weller; Teru Hideshima; Constantine S Mitsiades; Faith Davies; Richard LeBlanc; Laurence Catley; Deborah Doss; Kathleen Kelly; Mary McKenney; Julie Mechlowicz; Andrea Freeman; Reggie Deocampo; Rebecca Rich; Joan J Ryoo; Dharminder Chauhan; Kathe Balinski; Jerome B Zeldis; Kenneth C Anderson
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Blood 2002;100(9):3063-7.
2002: Nicholas Mitsiades; Constantine S Mitsiades; Vassiliki Poulaki; Dharminder Chauhan; Galinos Fanourakis; Xuesong Gu; Charles Bailey; Marie Joseph; Towia Libermann; Steve P Treon; Nikhil C Munshi; Paul G Richardson; Teru Hideshima; Kenneth C Anderson
Molecular sequelae of proteasome inhibition in human multiple myeloma cells.
Proceedings of the National Academy of Sciences of the United States of America 2002;99(22):14374-9.
2002: Dharminder Chauhan; Laurence Catley; Teru Hideshima; Guilan Li; Richard LeBlanc; Deepak Gupta; Martin Sattler; Paul Richardson; Robert Schlossman; klaus podar; Edie Weller; Nikhil C Munshi; Kenneth C Anderson
2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells.
Blood 2002;100(6):2187-94.
2002: Masaharu Akiyama; Teru Hideshima; Nikhil C Munshi; Kenneth C Anderson
Telomerase inhibitors as anticancer therapy.
Current medicinal chemistry. Anti-cancer agents 2002;2(5):567-75.
2002: Deepak Gupta; Teru Hideshima; Kenneth C Anderson
Novel biologically based therapeutic strategies in myeloma.
Reviews in clinical and experimental hematology 2002;6(3):301-24.
2002: Boris Lin; klaus podar; Deepak Gupta; Yu-Tzu Tai; Sigui Li; Edie Weller; Teru Hideshima; Suzanne Lentzsch; Faith Davies; Cheng Li; Ellen Weisberg; Robert Schlossman; Paul G Richardson; James D Griffin; Jeanette Wood; Nikhil C Munshi; Kenneth C Anderson
The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment.
Cancer research 2002;62(17):5019-26.
2002: Richard LeBlanc; Laurence Catley; Teru Hideshima; Suzanne Lentzsch; Constantine S Mitsiades; Nicholas Mitsiades; Donna Neuberg; Olga Goloubeva; Christine S Pien; Julian Adams; Deepak Gupta; Paul G Richardson; Nikhil C Munshi; Kenneth C Anderson
Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.
Cancer research 2002;62(17):4996-5000.
2002: Constantine S Mitsiades; Nicholas Mitsiades; Vassiliki Poulaki; Robert Schlossman; Masaharu Akiyama; Dharminder Chauhan; Teru Hideshima; Steve P Treon; Nikhil C Munshi; Paul G Richardson; Kenneth C Anderson
Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications.
Oncogene 2002;21(37):5673-83.
2002: Toshiaki Hayashi; Teru Hideshima; Masaharu Akiyama; Paul Richardson; Robert Schlossman; Dharminder Chauhan; Nikhil C Munshi; Samuel Waxman; Kenneth C Anderson
Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment.
Molecular cancer therapeutics 2002;1(10):851-60.
2002: Nikhil C Munshi; Teru Hideshima; Dharminder Chauhan; Paul G Richardson; Kenneth C Anderson
Novel biologically based therapies for multiple myeloma.
International journal of hematology 2002;76 Suppl 1():340-1.
2002: Christian Brander; Noopur Raje; Paula G O'Connor; Faith Davies; Jennifer Davis; Darminder Chauhan; Teru Hideshima; Jeff Martin; Dennis H Osmond; Dean H Kedes; Bruce D Walker; David T Scadden; Kenneth C Anderson
Absence of biologically important Kaposi sarcoma-associated herpesvirus gene products and virus-specific cellular immune responses in multiple myeloma.
Blood 2002;100(2):698-700.
2002: Deepak Gupta; klaus podar; Yu-Tzu Tai; Boris Lin; Teru Hideshima; Masaharu Akiyama; Richard LeBlanc; Laurence Catley; Nicholas Mitsiades; Constantine S Mitsiades; Dharminder Chauhan; Nikhil C Munshi; Kenneth C Anderson
beta-lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cells.
Experimental hematology 2002;30(7):711-20.
2002: Masaharu Akiyama; Teru Hideshima; Toshiaki Hayashi; Yu-Tzu Tai; Constantine S Mitsiades; Nicholas Mitsiades; Dharminder Chauhan; Paul Richardson; Nikhil C Munshi; Kenneth C Anderson
Cytokines modulate telomerase activity in a human multiple myeloma cell line.
Cancer research 2002;62(13):3876-82.
2002: Nicholas Mitsiades; Constantine S Mitsiades; Vassiliki Poulaki; Dharminder Chauhan; Paul G Richardson; Teru Hideshima; Nikhil C Munshi; Steve P Treon; Kenneth C Anderson
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications.
Blood 2002;99(12):4525-30.
2002: Nicholas Mitsiades; Constantine S Mitsiades; Vassiliki Poulaki; Dharminder Chauhan; Paul G Richardson; Teru Hideshima; Nikhil C Munshi; Steve P Treon; Kenneth C Anderson
Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications.
Blood 2002;99(11):4079-86.
2002: Teru Hideshima; Dharminder Chauhan; Paul Richardson; Constantine S Mitsiades; Nicholas Mitsiades; Toshiaki Hayashi; Nikhil C Munshi; Lenny Dang; Alfredo Castro; Vito J Palombella; Julian Adams; Kenneth C Anderson
NF-kappa B as a therapeutic target in multiple myeloma.
The Journal of biological chemistry 2002;277(19):16639-47.
2002: Teru Hideshima; Dharminder Chauhan; Toshiaki Hayashi; klaus podar; Masaharu Akiyama; Deepak Gupta; Paul Richardson; Nikhil C Munshi; Kenneth C Anderson
The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma.
Molecular cancer therapeutics 2002;1(7):539-44.
2002: Paul G Richardson; Teru Hideshima; Kenneth C Anderson
Thalidomide in multiple myeloma.
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2002;56(3):115-28.
2002: Dharminder Chauhan; Daniel Auclair; Elisabeth K Robinson; Teru Hideshima; Guilan Li; klaus podar; Deepak Gupta; Paul Richardson; Robert Schlossman; Nancy L Krett; Lan Bo Chen; Nikhil C Munshi; Kenneth C Anderson
Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays.
Oncogene 2002;21(9):1346-58.
2002: Paul G Richardson; Teru Hideshima; Kenneth C Anderson
Thalidomide: emerging role in cancer medicine.
Annual review of medicine 2002;53():629-57.
2001: Deepak Gupta; Steve P Treon; Y Shima; Teru Hideshima; klaus podar; Yu-Tzu Tai; Boris Lin; Suzanne Lentzsch; Faith E Davies; Dharminder Chauhan; Robert Schlossman; Paul Richardson; P Ralph; Lei Wu; Faribourz Payvandi; G Muller; David I Stirling; Kenneth C Anderson
Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications.
Leukemia 2001;15(12):1950-61.
2001: Teru Hideshima; Dharminder Chauhan; klaus podar; Robert Schlossman; Paul Richardson; Kenneth C Anderson
Novel therapies targeting the myeloma cell and its bone marrow microenvironment.
Seminars in oncology 2001;28(6):607-12.
2001: Teru Hideshima; N Nakamura; Dharminder Chauhan; Kenneth C Anderson
Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma.
Oncogene 2001;20(42):5991-6000.
2001: Constantine S Mitsiades; Steve P Treon; Nicholas Mitsiades; Y Shima; Paul Richardson; Robert Schlossman; Teru Hideshima; Kenneth C Anderson
TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications.
Blood 2001;98(3):795-804.
2001: Teru Hideshima; Dharminder Chauhan; Robert Schlossman; Paul Richardson; Kenneth C Anderson
The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications.
Oncogene 2001;20(33):4519-27.
2001: klaus podar; Yu-Tzu Tai; Faith E Davies; Suzanne Lentzsch; Martin Sattler; Teru Hideshima; Boris K Lin; Deepak Gupta; Y Shima; Dharminder Chauhan; Constantine S Mitsiades; Noopur Raje; Paul Richardson; Kenneth C Anderson
Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration.
Blood 2001;98(2):428-35.
2001: Dharminder Chauhan; Teru Hideshima; S Rosen; J C Reed; S Kharbanda; Kenneth C Anderson
Apaf-1/cytochrome c-independent and Smac-dependent induction of apoptosis in multiple myeloma (MM) cells.
The Journal of biological chemistry 2001;276(27):24453-6.
2001: Faith E Davies; Noopur Raje; Teru Hideshima; Suzanne Lentzsch; Gloria Young; Yu-Tzu Tai; Boris Lin; klaus podar; Deepak Gupta; Dharminder Chauhan; Steve P Treon; Paul G Richardson; Robert Schlossman; G J Morgan; George W Muller; David I Stirling; Kenneth C Anderson
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.
Blood 2001;98(1):210-6.
2001: Teru Hideshima; Paul Richardson; Dharminder Chauhan; Vito J Palombella; Peter J Elliott; Julian Adams; Kenneth C Anderson
The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.
Cancer research 2001;61(7):3071-6.
2000: Yu-Tzu Tai; G Teoh; Boris Lin; FE Davies; Dharminder Chauhan; Steve P Treon; Noopur Raje; Teru Hideshima; Y Shima; klaus podar; Kenneth C Anderson
Ku86 variant expression and function in multiple myeloma cells is associated with increased sensitivity to DNA damage.
Journal of immunology (Baltimore, Md. : 1950) 2000;165(11):6347-55.
2000: Steve P Treon; P Maimonis; D Bua; Gloria Young; Noopur Raje; Joseph A Mollick; Dharminder Chauhan; Yu-Tzu Tai; Teru Hideshima; Y Shima; JH Hilgers; Silvia von Mensdorff-Pouilly; Andrew R Belch; Linda M Pilarski; Kenneth C Anderson
Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma.
Blood 2000;96(9):3147-53.
2000: Teru Hideshima; Dharminder Chauhan; Y Shima; Noopur Raje; Faith E Davies; Yu-Tzu Tai; Steve P Treon; Boris Lin; Robert Schlossman; Paul Richardson; G Muller; David I Stirling; Kenneth C Anderson
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.
Blood 2000;96(9):2943-50.
2000: Dharminder Chauhan; Pramod Pandey; Teru Hideshima; Steve P Treon; Noopur Raje; Faith E Davies; Y Shima; Yu-Tzu Tai; S Rosen; S Avraham; Surender Kharbanda; Kenneth C Anderson
SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells.
The Journal of biological chemistry 2000;275(36):27845-50.
2000: Noopur Raje; G Kica; Dharminder Chauhan; Yana Zhang; G Teoh; Steve P Treon; Teru Hideshima; Jian-Hong Deng; Shou-Jiang Gao; M Alsina; J Wally; FE Davies; Yu-Tzu Tai; Geraldine S Pinkus; Jack L Pinkus; Martha Skinner; Raymond Comenzo; Kenneth C Anderson
Kaposi's sarcoma-associated herpesvirus gene sequences are detectable at low copy number in primary amyloidosis.
Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2000;7(2):126-32.
2000: Teru Hideshima; Dharminder Chauhan; G Teoh; Noopur Raje; Steve P Treon; Yu-Tzu Tai; Y Shima; Kenneth C Anderson
Characterization of signaling cascades triggered by human interleukin-6 versus Kaposi's sarcoma-associated herpes virus-encoded viral interleukin 6.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(3):1180-9.
2000: Yu-Tzu Tai; G Teoh; Y Shima; Dharminder Chauhan; Steve P Treon; Noopur Raje; Teru Hideshima; FE Davies; Kenneth C Anderson
Isolation and characterization of human multiple myeloma cell enriched populations.
Journal of immunological methods 2000;235(1-2):11-9.
2000: G Teoh; Yu-Tzu Tai; Mitsuyoshi Urashima; S Shirahama; M Matsuzaki; Dharminder Chauhan; Steve P Treon; Noopur Raje; Teru Hideshima; Y Shima; Kenneth C Anderson
CD40 activation mediates p53-dependent cell cycle regulation in human multiple myeloma cell lines.
Blood 2000;95(3):1039-46.
1999: Dharminder Chauhan; Teru Hideshima; P Pandey; Steve P Treon; G Teoh; Noopur Raje; S Rosen; N Krett; H Husson; S Avraham; S Kharbanda; Kenneth C Anderson
RAFTK/PYK2-dependent and -independent apoptosis in multiple myeloma cells.
Oncogene 1999;18(48):6733-40.
1999: Dharminder Chauhan; Teru Hideshima; Steve P Treon; G Teoh; Noopur Raje; S Yoshihimito; Yu-Tzu Tai; W Li; J Fan; James A DeCaprio; Kenneth C Anderson
Functional interaction between retinoblastoma protein and stress-activated protein kinase in multiple myeloma cells.
Cancer research 1999;59(6):1192-5.
1999: Dharminder Chauhan; A Bharti; Noopur Raje; EA Gustafson; Geraldine S Pinkus; Jack L Pinkus; G Teoh; Teru Hideshima; Steve P Treon; Joyce Diane Fingeroth; Kenneth C Anderson
Detection of Kaposi's sarcoma herpesvirus DNA sequences in multiple myeloma bone marrow stromal cells.
Blood 1999;93(5):1482-6.